Association of polymorphisms in TGFB1, XRCC1, XRCC3 genes and CD8 T-lymphocyte apoptosis with adverse effect of radiotherapy for prostate cancer.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
09 Dec 2022
09 Dec 2022
Historique:
received:
04
05
2022
accepted:
28
11
2022
entrez:
9
12
2022
pubmed:
10
12
2022
medline:
15
12
2022
Statut:
epublish
Résumé
The genetic background of each person might affect the severity of radiotherapy (RT)-induced normal tissue toxicity. The aim of study was to evaluate the influence of TGFB1 C-509T and Leu10Pro, XRCC1 Arg280His and XRCC3 Thr241Met polymorphisms as well as the level of radiation-induced CD8 T-lymphocyte apoptosis (RILA) on adverse effects of RT for prostate cancer (PCa). The study included 88 patients with localized or locally advanced PCa who were treated with RT. The polymorphisms were determined by PCR-RFLP analysis on DNA from peripheral blood mononuclear cells. RILA values were measured by flow cytometry. We found that CT genotype of TGFB1 C-509T could be protective biomarker for acute genitourinary (GU) and gastrointestinal (GI) radiotoxicity, while Thr variant of XRCC3 Thr241Met could predict the risk for acute GU radiotoxicity. Correlation between RILA values and toxicity was not detected. Univariate logistic regression analysis showed that Gleason score and risk group were risk factors for late GU, while for late GI radiotoxicity it was diabetes mellitus type 2. However, in multivariate model those were not proven to be significant and independent risk factors. Identification of assays combination predicting individual radiosensitivity is a crucial step towards personalized RT approach.
Identifiants
pubmed: 36494413
doi: 10.1038/s41598-022-25328-6
pii: 10.1038/s41598-022-25328-6
pmc: PMC9734114
doi:
Substances chimiques
X-ray Repair Cross Complementing Protein 1
0
TGFB1 protein, human
0
Transforming Growth Factor beta1
0
XRCC1 protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
21306Informations de copyright
© 2022. The Author(s).
Références
Expert Rev Mol Diagn. 2017 Feb;17(2):119-127
pubmed: 27936985
Nucleic Acids Res. 1988 Feb 11;16(3):1215
pubmed: 3344216
Clin Transl Radiat Oncol. 2019 Jun 10;18:1-8
pubmed: 31341970
Asian Pac J Cancer Prev. 2012;13(12):6121-8
pubmed: 23464416
EBioMedicine. 2015 Oct 25;2(12):1965-73
pubmed: 26844275
Cancer Res. 2003 May 15;63(10):2610-5
pubmed: 12750287
Int J Radiat Oncol Biol Phys. 2013 Feb 1;85(2):393-9
pubmed: 22658438
Cancer Genomics Proteomics. 2015 Nov-Dec;12(6):359-67
pubmed: 26543082
Mol Cell. 2002 Aug;10(2):387-95
pubmed: 12191483
Radiother Oncol. 2003 Nov;69(2):127-35
pubmed: 14643949
Hum Genet. 2006 Nov;120(4):461-9
pubmed: 16896927
N Engl J Med. 2000 May 4;342(18):1350-8
pubmed: 10793168
PLoS One. 2015 Jun 19;10(6):e0130388
pubmed: 26091483
Clin Oncol (R Coll Radiol). 2014 May;26(5):301-8
pubmed: 24702740
Radiat Res. 2010 Apr;173(4):505-11
pubmed: 20334523
Int J Radiat Oncol Biol Phys. 2008 Mar 1;70(3):752-9
pubmed: 17689884
Crit Rev Oncol Hematol. 2012 Dec;84 Suppl 1:e35-41
pubmed: 20869261
Radiother Oncol. 2012 May;103(2):206-9
pubmed: 22385796
Int J Radiat Oncol Biol Phys. 2012 Jun 1;83(2):504-11
pubmed: 22079734
Radiother Oncol. 2005 Apr;75(1):18-21
pubmed: 15878096
Radiother Oncol. 2011 Mar;98(3):387-93
pubmed: 21345510
Front Oncol. 2021 Mar 04;10:627379
pubmed: 33747899
Oncotarget. 2018 Aug 24;9(66):32680-32689
pubmed: 30220974
Int J Radiat Biol. 2003 Feb;79(2):137-43
pubmed: 12569017
Carcinogenesis. 2010 Apr;31(4):648-53
pubmed: 20100738
Meta Gene. 2015 May 22;5:1-8
pubmed: 26042205
Tumori. 2017 Sep 18;103(5):395-404
pubmed: 28885678
Radiother Oncol. 2002 Aug;64(2):131-40
pubmed: 12242122
Prostate Cancer. 2015;2015:624736
pubmed: 26697225
Int J Radiat Oncol Biol Phys. 2005 Mar 15;61(4):1019-34
pubmed: 15752881
Clin Cancer Res. 2006 Apr 15;12(8):2545-54
pubmed: 16638864
Radiother Oncol. 2012 Dec;105(3):289-95
pubmed: 23199655
Cancer Biother Radiopharm. 2010 Dec;25(6):681-5
pubmed: 21204762
Carcinogenesis. 2001 Sep;22(9):1437-45
pubmed: 11532866
Radiother Oncol. 2010 Oct;97(1):9-14
pubmed: 20096948
Environ Health Perspect. 2003 Nov;111(15):1843-50
pubmed: 14630517
Radiat Res. 2008 Jul;170(1):49-59
pubmed: 18582155
Front Oncol. 2020 Oct 15;10:541281
pubmed: 33178576
Mutat Res. 2009 Jun 18;666(1-2):8-15
pubmed: 19481674
Indian J Hematol Blood Transfus. 2015 Sep;31(3):332-8
pubmed: 26085717
J Clin Oncol. 2009 Jul 10;27(20):3370-8
pubmed: 19380441
Am Fam Physician. 2010 Aug 15;82(4):381-8, 394
pubmed: 20704169
Clin Cancer Res. 2005 Oct 15;11(20):7426-33
pubmed: 16243816
JAMA Oncol. 2018 Dec 1;4(12):1751-1757
pubmed: 30027292
Genome Med. 2011 Aug 23;3(8):52
pubmed: 21861849
Hum Mol Genet. 1999 Jan;8(1):93-7
pubmed: 9887336
Clin Cancer Res. 2008 Oct 1;14(19):6284-8
pubmed: 18829510
J Clin Epidemiol. 1996 Dec;49(12):1373-9
pubmed: 8970487
Br J Cancer. 2007 Mar 26;96(6):1001-7
pubmed: 17325707
Int J Med Sci. 2012;9(3):193-9
pubmed: 22408567
Mutat Res. 2004 Oct 4;554(1-2):319-33
pubmed: 15450429
Int J Radiat Biol. 2006 Aug;82(8):577-86
pubmed: 16966185